Logo image of UPB

UPSTREAM BIO INC (UPB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:UPB - US91678A1079 - Common Stock

28.6 USD
+0.6 (+2.14%)
Last: 11/28/2025, 8:04:36 PM
28 USD
-0.6 (-2.1%)
After Hours: 11/28/2025, 8:04:36 PM
Fundamental Rating

3

Overall UPB gets a fundamental rating of 3 out of 10. We evaluated UPB against 533 industry peers in the Biotechnology industry. UPB has a great financial health rating, but its profitability evaluates not so good. UPB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

UPB had negative earnings in the past year.
UPB had a negative operating cash flow in the past year.
UPB Yearly Net Income VS EBIT VS OCF VS FCFUPB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

UPB has a Return On Assets of -31.38%. This is in the better half of the industry: UPB outperforms 67.04% of its industry peers.
The Return On Equity of UPB (-32.43%) is better than 75.84% of its industry peers.
Industry RankSector Rank
ROA -31.38%
ROE -32.43%
ROIC N/A
ROA(3y)-59.22%
ROA(5y)N/A
ROE(3y)-136.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UPB Yearly ROA, ROE, ROICUPB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UPB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UPB Yearly Profit, Operating, Gross MarginsUPB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

UPB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UPB has more shares outstanding
There is no outstanding debt for UPB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UPB Yearly Shares OutstandingUPB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
UPB Yearly Total Debt VS Total AssetsUPB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 72.47 indicates that UPB is not in any danger for bankruptcy at the moment.
UPB has a Altman-Z score of 72.47. This is amongst the best in the industry. UPB outperforms 98.50% of its industry peers.
There is no outstanding debt for UPB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 72.47
ROIC/WACCN/A
WACC8.66%
UPB Yearly LT Debt VS Equity VS FCFUPB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 32.67 indicates that UPB has no problem at all paying its short term obligations.
With an excellent Current ratio value of 32.67, UPB belongs to the best of the industry, outperforming 98.50% of the companies in the same industry.
UPB has a Quick Ratio of 32.67. This indicates that UPB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 32.67, UPB belongs to the top of the industry, outperforming 98.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 32.67
Quick Ratio 32.67
UPB Yearly Current Assets VS Current LiabilitesUPB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for UPB have decreased strongly by -99.70% in the last year.
The Revenue has decreased by -0.42% in the past year.
EPS 1Y (TTM)-99.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.95%
Revenue 1Y (TTM)-0.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.52%

3.2 Future

Based on estimates for the next years, UPB will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.96% on average per year.
The Revenue is expected to grow by 46.18% on average over the next years. This is a very strong growth
EPS Next Y64.81%
EPS Next 2Y26.18%
EPS Next 3Y15.16%
EPS Next 5Y8.96%
Revenue Next Year10.82%
Revenue Next 2Y-25.68%
Revenue Next 3Y-26.3%
Revenue Next 5Y46.18%

3.3 Evolution

UPB Yearly Revenue VS EstimatesUPB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
UPB Yearly EPS VS EstimatesUPB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

UPB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UPB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPB Price Earnings VS Forward Price EarningsUPB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPB Per share dataUPB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

UPB's earnings are expected to grow with 15.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.18%
EPS Next 3Y15.16%

More info and screens

0

5. Dividend

5.1 Amount

UPB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UPSTREAM BIO INC

NASDAQ:UPB (11/28/2025, 8:04:36 PM)

After market: 28 -0.6 (-2.1%)

28.6

+0.6 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-10 2026-03-10
Inst Owners79.85%
Inst Owner Change-6.04%
Ins Owners0.05%
Ins Owner Change0%
Market Cap1.55B
Revenue(TTM)2.80M
Net Income(TTM)-122.77M
Analysts82.22
Price Target62.22 (117.55%)
Short Float %7.28%
Short Ratio7.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.31%
Min EPS beat(2)-19.62%
Max EPS beat(2)20.24%
EPS beat(4)1
Avg EPS beat(4)-46.15%
Min EPS beat(4)-181.12%
Max EPS beat(4)20.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)98.52%
Min Revenue beat(2)4.84%
Max Revenue beat(2)192.2%
Revenue beat(4)4
Avg Revenue beat(4)81.45%
Min Revenue beat(4)4.84%
Max Revenue beat(4)192.2%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.67%
PT rev (3m)-18.67%
EPS NQ rev (1m)8.38%
EPS NQ rev (3m)6.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.31%
Revenue NQ rev (1m)-7.2%
Revenue NQ rev (3m)-7.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 552.18
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 4.08
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-3.31
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.26
OCFYN/A
SpS0.05
BVpS7.01
TBVpS7.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.38%
ROE -32.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.22%
ROA(5y)N/A
ROE(3y)-136.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.44%
Cap/Sales 10.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.67
Quick Ratio 32.67
Altman-Z 72.47
F-Score3
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)661.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)11.46%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.95%
EPS Next Y64.81%
EPS Next 2Y26.18%
EPS Next 3Y15.16%
EPS Next 5Y8.96%
Revenue 1Y (TTM)-0.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.52%
Revenue Next Year10.82%
Revenue Next 2Y-25.68%
Revenue Next 3Y-26.3%
Revenue Next 5Y46.18%
EBIT growth 1Y-93.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.68%
EBIT Next 3Y-36.38%
EBIT Next 5YN/A
FCF growth 1Y-56.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.02%
OCF growth 3YN/A
OCF growth 5YN/A

UPSTREAM BIO INC / UPB FAQ

What is the fundamental rating for UPB stock?

ChartMill assigns a fundamental rating of 3 / 10 to UPB.


Can you provide the valuation status for UPSTREAM BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to UPSTREAM BIO INC (UPB). This can be considered as Overvalued.


What is the profitability of UPB stock?

UPSTREAM BIO INC (UPB) has a profitability rating of 1 / 10.


How financially healthy is UPSTREAM BIO INC?

The financial health rating of UPSTREAM BIO INC (UPB) is 8 / 10.


What is the earnings growth outlook for UPSTREAM BIO INC?

The Earnings per Share (EPS) of UPSTREAM BIO INC (UPB) is expected to grow by 64.81% in the next year.